ESMO 2023 | Bringing change with TTFields therapy in ovarian cancer

Jalid Sehouli, MD, Charité Universitätsmedizin Berlin, discusses the challenges in treating relapsed ovarian cancer despite advancements in surgery, chemotherapy, and maintenance treatments and explores a novel approach using tumor-treating fields (TTfields), proven effective in brain tumors like glioblastoma and mesothelioma. Despite a Phase III trial, ENGOT-ov50/INNOVATE-3 (NCT03940196) trial, failing its primary endpoint of overall-survival (OS), Dr Sehouli remains optimistic about identifying specific groups within the heterogeneous cohort of platinum-resistant ovarian cancer that may benefit from TTfields, especially in combination with weekly paclitaxel chemotherapy. He emphasizes the need for a modified treatment paradigm, suggesting TTfields as a promising avenue for changing the approach to women’s cancer treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.